Skip to main content
. 2019 Dec 16;122(4):506–516. doi: 10.1038/s41416-019-0673-5

Table 2.

Effect of DUSP4 depletion on response to MEK inhibition in BRAF wild-type melanoma cells.

Cell line CHL-1 SK-MEL-23
MEK inhibitor Selumetinib Trametinib Selumetinib Trametinib
Fold increase in SF50 6.71 ± 1.30 6.85 ± 2.42 2.94 ± 0.40 2.48 ± 0.44
p-value 0.0072 0.0605 0.0048 0.02

The table shows mean ± SEM fold increase in SF50 values in DUSP4-depleted CHL-1 and SK-MEL-23 cells (n = 6 in each case; data analysed using two-tailed t test).